2.3 Utility Requirements & USPTO Utility Guidelines

2.3 Utility Requirements & USPTO Utility Guidelines

In addition to fitting within a statutory category under 35 U.S.C. § 101, an invention must be "useful." The utility requirement derives from Article I, Section 8, Clause 8 of the U.S. Constitution, which authorizes Congress to promote the progress of the "useful Arts."

---

The USPTO Utility Examination Guidelines (MPEP § 2107)

To enforce the utility threshold consistently, the USPTO established the Utility Examination Guidelines (MPEP § 2107). An application meets the § 101 utility requirement if it discloses a well-established utility OR asserts a utility that satisfies three cumulative criteria:

1. Specific Utility: The utility must be specific to the claimed subject matter, rather than a generic utility that could apply broadly to an entire class of chemical compounds or biological molecules.
2. Substantial Utility: The invention must have a real-world, immediate utility in its present form without requiring further research or development to identify a practical use.
3. Credible Utility: The asserted utility must be believable to a Person Having Ordinary Skill in the Art (POSITA) in light of the specification disclosure and state of the art.

---

Landmark Precedents: Brenner v. Manson & In re Fisher

The Brenner v. Manson Standard

In Brenner v. Manson, 383 U.S. 519 (1966), the Supreme Court established the foundational standard for substantial utility. The applicant claimed a process for producing a novel steroid compound, admitting that the compound's therapeutic efficacy was unknown and under investigation.

• The Supreme Court rejected the claim, establishing the famous rule:

  "A patent is not a hunting license. It is not a reward for the search, but but for its successful completion."

• A chemical compound or process is not useful under § 101 merely because it is the object of scientific research.

Gene Sequences & ESTs: In re Fisher

In In re Fisher, 421 F.3d 1365 (Fed. Cir. 2005), the Federal Circuit applied Brenner v. Manson to biotechnology claims involving Expressed Sequence Tags (ESTs):

• The applicant claimed five ESTs (short cDNA sequences) useful for detecting nucleic acid expression in maize.
• Because the applicant did not know the structure, function, or identity of the underlying genes expressed by the ESTs, the court held that using ESTs merely as generic gene probes or chromosome markers was a "throwaway utility."
• ESTs lacking known underlying gene functions fail both specific and substantial utility requirements under § 101.

---

Throwaway vs. Well-Known Utilities

Throwaway Utilities (Insufficient)

Utilities that can be asserted for virtually any physical object fail the substantial utility test. Examples of throwaway utilities that do NOT satisfy § 101:

• Using a novel chemical compound as a paperweight, landfill material, or ship ballast.
• Using an uncharacterized DNA sequence as a generic molecular weight marker.
• Using a complex mechanical device as a doorstop.

Well-Known Utilities (Sufficient Without Explicit Assertion)

If a utility for an invention is well-established—meaning a POSITA would immediately appreciate the utility without needing it spelled out—the applicant does not need to explicitly state the utility in the specification (MPEP § 2107.01).

• Example: Claiming a hand-held tool comprising a heavy iron head and wooden handle (a hammer) has a well-known utility for driving nails.

---

Pharmaceutical Claims & In Vitro / In Vivo Evidentiary Standards

A critical Patent Bar exam topic is how examiners evaluate utility for pharmaceutical and therapeutic claims:

1. Clinical Human Trials NOT Required: The USPTO does not require human clinical trial data (FDA Phase I/II/III results) to establish credible utility under § 101.
2. In Vitro & Animal Model Data Are Sufficient: Pharmacological activity demonstrated through in vitro tissue assays or in vivo animal model testing is fully sufficient to establish credible utility for therapeutic claims, unless extraordinary evidence contradicts the findings (MPEP § 2107.02).
3. Safety & Efficacy vs. Patent Utility: FDA approval requires proof of safety and commercial efficacy. In contrast, Patent Office utility requires only a credible assertion of specific and substantial practical usefulness.

---

Perpetual Motion Machines & Inoperability Rejection Procedures

When a patent application claims an invention that violates fundamental natural laws—such as a perpetual motion machine or a device violating the First or Second Law of Thermodynamics—the examiner applies a specific rejection protocol (MPEP § 2107.01):

Examiner Dual Rejection Protocol

1. Rejection under 35 U.S.C. § 101: Rejected for lack of credible utility because the invention is physically inoperable.
2. Rejection under 35 U.S.C. § 112(a): Rejected for lack of enablement because an inoperable invention cannot be described in a manner that enables a POSITA to make and use it.

Rebutting the Rejection (37 C.F.R. § 1.91)

To overcome a perpetual motion or inoperability rejection, the applicant cannot rely solely on argument or theoretical assertions. Under 37 C.F.R. § 1.91, the USPTO Director or Examiner may require the applicant to submit a working model or physical demonstration proving operability.